|
- ZYNYZ® (retifanlimab-dlwr) | Official Patient Site
ZYNYZ is a medicine that may treat certain types of cancers by working with your immune system ZYNYZ can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work These problems can sometimes become severe or life-threatening and can lead to death
- Retifanlimab-dlwr - NCI - National Cancer Institute
Retifanlimab-dlwr is a type of drug called an immune checkpoint inhibitor It works by binding to the protein PD-1 on the surface of certain immune cells called T cells, which keeps cancer cells from suppressing the immune system
- ZYNYZ® (retifanlimab-dlwr) for SCAC MCC | Official HCP Site
ZYNYZ, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC)
- Retifanlimab Uses, Side Effects Warnings - Drugs. com
What is retifanlimab? Retifanlimab is used to treat a type of skin cancer called Merkel cell carcinoma in adults, when the cancer has spread to other parts of the body (metastatic) or returned
- FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as
On May 15, 2025, the Food and Drug Administration approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable
- Retifanlimab - Memorial Sloan Kettering Cancer Center
Retifanlimab Adult Medication This information from Lexicomp ® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider
- Retifanlimab: First Approval - PubMed
Retifanlimab (retifanlimab-dlwr; ZYNYZ TM) is a programmed cell death 1 receptor-blocking antibody that is being developed by Incyte Corporation for the treatment of solid tumours, both as monotherapy and in combination with other agents
- Retifanlimab Adds FDA-Approved Option to Merkel Cell Carcinoma . . .
Retifanlimab is an IgG4 monoclonal antibody that targets PD-1 1 The agent received accelerated approval from the FDA in March 2023 for the treatment of adult patients with metastatic or
|
|
|